About 22 results found for searched term "Multi-kinase-IN-4" (0.131 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M43540 | Multi-kinase-IN-4 | VEGFR/PDGFR |
| Multi-kinase-IN-4 is multi-targeted kinase inhibitor, including VEGFR2, EGFR, HER2, and CDK2, with IC50 values of 0.33, 0.22, 0.18 and 2.09 μM, respectively. | ||
| M1669 | Regorafenib | VEGFR/PDGFR |
| BAY 73-4506 | ||
| Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively. | ||
| M1815 | KW-2449 | FLT3 |
| KW2449 | ||
| KW-2449 is a novel multitargeted kinase inhibitor of FLT3, ABL and Aurora kinase with IC50 values of 6.6 nM, 14 nM and 48 nM. | ||
| M1826 | Sunitinib Malate | VEGFR/PDGFR |
| SU-11248, Sutent | ||
| Sunitinib is a multitargeted tyrosine kinase inhibitor of VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively. | ||
| M1841 | Lenvatinib | VEGFR/PDGFR |
| E7080 | ||
| Lenvatinib (E7080) is a potent inhibitor of multiple tyrosine kinases, including VEGF-R3 tyrosine kinase (IC50=5.2 nM) and VEGF-R2 tyrosine kinase (IC50=4.0 nM). | ||
| M1956 | Apatinib mesylate | VEGFR/PDGFR |
| Rivoceranib mesylate; YN968D1 | ||
| Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor of VEGFR2 with an IC50 of 2.43 nM. | ||
| M5029 | WHI-P180 | CDK |
| Janex 3 | ||
| Whi-p180 (Janex 3) is a multikinase inhibitor; The IC50 values of RET, KDR and EGFR were 5 nM, 66 nM and 4 μM, respectively. | ||
| M6158 | ARQ-087 | FGFR |
| Derazantinib | ||
| ARQ 087 is a novel, ATP competitive, small molecule, multi-kinase inhibitor with potent in vitro and in vivo activity against FGFR addicted cell lines and tumors. ARQ 087 exhibited IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3. | ||
| M7590 | A3 hydrochloride | PKA |
| A-3 hydrochloride | ||
| A-3 Hydrochloride is A potent, cellular permeable, reversible, atP-competitive, non-selective antagonist targeting multiple kinases. A-3 Hydrochloride is an inhibitor of PKA (Ki=4.3 µM), casein kinase II (Ki=5.1 µM), and myosin light chain kinase (MLCK) (Ki=7.4 µM). A-3 hydrochloride also inhibited PKC and casein kinase I activity with Ki of 47 µM and 80 µM, respectively. | ||
| M8949 | JI-101 | VEGFR/PDGFR |
| JI-101 is an orally available multi-kinase inhibitor of VEGFR2，PDGFRβ and EphB4 with potential antiangiogenic and antineoplastic activities. | ||
| M9009 | Ponatinib hydrochloride | Src-bcr-Abl |
| AP24534 HCl | ||
| Ponatinib hydrochloride is a potent, orally available multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. | ||
| M9429 | SU14813 | VEGFR/PDGFR |
| SU-14813 | ||
| SU14813 is a novel multiple receptor tyrosine kinase inhibitor with IC50s of 2, 50, 4, 15 nM for VEGFR-1, VEGFR-2, PDGFR-β and KIT. | ||
| M11240 | XL092 | TAM Receptor |
| JUN04542; Zanzalintinib | ||
| XL092 is an orally active, ATP-competitive inhibitor of multireceptor tyrosine kinases (RTKs), including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM and 7.2 nM in cell analysis, respectively. XL092 has antitumor activity. | ||
| M13592 | ENMD-2076 Tartrate | Aurora Kinase |
| ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively. | ||
| M14920 | Lenvatinib mesylate | VEGFR/PDGFR |
| E7080 mesylate | ||
| Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. | ||
| M27701 | Famitinib | VEGFR/PDGFR |
| SHR1020 | ||
| Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis. | ||
| M27723 | Amuvatinib hydrochloride | c-Kit |
| MP470 hydrochloride; HPK 56 hydrochloride | ||
| Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity. | ||
| M28063 | Famitinib malate | VEGFR/PDGFR |
| SHR1020 malate | ||
| Famitinib (SHR1020) malate, an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib malate induces cell apoptosis. Famitinib malate exerts powerful antitumor activity in human gastric cancer cells and xenografts, it can be used for the research of cancer. | ||
| M28184 | Debio 0617B | STAT |
| Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34+ stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors. | ||
| M30688 | SU14813 maleate | VEGFR/PDGFR |
| SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT. | ||
| M45307 | Multi-kinase-IN-6 | Casein Kinase |
| Multi-kinase-IN-6 is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1 and CDK2. In addition, Multi-kinase-IN-6 also showed antiproliferative activity against MCF7, HCT116 and EKVX, with IC50 values of 3.36 μM, 1.40 μM and 3.49 μM, respectively, and showed good apoptotic activity in MCF7 and HCT116 cells with cell-cycle arrest in G1/S and G1 phases. phase, with good apoptosis effect. | ||
| M49558 | Antitumor agent-123 | JAK |
| Antitumor agent-123 effectively inhibits multiple kinase targets with anti-cancer effects, including JAK2, JAK3, HDAC1 and HDAC6, with IC50 values of 34.6 and 2.6 μM for JAK2 and JAK3, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
